iMOL, an Al-driven company focused on novel drug discovery
Became a JLABS Singapore member company in 2026
ABOUT
US
Leveraging industry expertise, breakthroughs in AI technology, in-depth data governance capabilities, and robust software and hardware capabilities, the company has developed a multimodal AI 3D generation model focused on small molecules.
Based on the GPT/Transformer architecture and integrated with geometric deep learning technology, this model can accurately generate molecules that match the targets and extend to multiple modalities. In addition, the company can provide customized solutions for the industry.
Currently, pharmaceutical enterprises and research institutions worldwide utilize this AI platform for early-stage R&D activities.
2026 to future
AI Agent
V 5.0
- Redefining and optimizing the new paradigm for drug discovery, centered on generative Al models.
- Deep convergence of Large Language Models and Vertical Domain Large Models.
- Molecular generative models, wet-lab data and a series of R&D tools together to form dedicated Al Agents.
2025
- Using wet-lab data by RAG and reinforcement learning to improve the performance of the generative AI
- Expanding to covalent compounds, molecular glues, peptides, and other modalities
AI 3D Molecule Generation Models Enhanced by Wet-Lab Data
V 4.0
2023 – 2024
- Introduced Transformer architecture
- Enabled richer multimodal data of binding pockets and molecule interactions
Multimodal AI 3D Molecule Generation with LLM Framework
V 3.0
2021 – 2022
- Introduced the unique molecular constraint (experimental electron density)
- Molecule generation based on binding pockets and fixed substructure
AI 3D Molecule Generation Based on Pockets
V 2.0
2018 – 2020
- Scaffold hopping and transformation from reference molecules.
AI 2D Molecule Generation Based on Ligands
V 1.0
Our Mission
Our Vision
Expand the Boundaries of Life, Find Cures for Every Disease
Define New Paradigm for Faster and Better Drug Discovery